Renal Outcomes of GLP-1 Receptor Agonists and Tirzepatide Across CKD Stages and Metabolic Phenotypes (Type 2 Diabetes and/or Overweight/Obesity): A Scoping Review - PubMed
3 hours ago
- #GLP-1 receptor agonists
- #Type 2 diabetes
- #Chronic kidney disease
- GLP-1 receptor agonists and tirzepatide show potential cardiorenal benefits in patients with type 2 diabetes and/or overweight/obesity.
- The review included 35 studies, highlighting renal benefits such as reduced composite kidney outcomes and slower eGFR decline with semaglutide, dulaglutide, and liraglutide.
- Tirzepatide demonstrated consistent reductions in albuminuria and attenuation of eGFR decline compared to insulin glargine.
- Other agents like efpeglenatide, cotadutide, exenatide, and lixisenatide showed antiproteinuric effects.
- Renal benefits were partly independent of glycemic and weight effects.
- Evidence is strongest for semaglutide and dulaglutide, with emerging data for tirzepatide and other incretin-based agents.
- The findings provide a structured evidence map to inform future clinical decision-making.